Robert Cowan, MD

home / authors / robert-cowan-md

Articles

Therapies in Development for Acute Migraine

Therapies in Development for Acute Migraine

Robert Cowan, MD;David W. Dodick, MD
October 30th 2020
Ubrogepant: Treatment for Acute Migraine

Ubrogepant: Treatment for Acute Migraine

Robert Cowan, MD;David W. Dodick, MD
October 30th 2020
Rimegepant: Treatment for Acute Migraine

Rimegepant: Treatment for Acute Migraine

Robert Cowan, MD;David W. Dodick, MD
October 30th 2020
Patient Selection for Acute Migraine Therapy

Patient Selection for Acute Migraine Therapy

Robert Cowan, MD;David W. Dodick, MD
October 30th 2020
Acute Migraine Treatment Goals

Acute Migraine Treatment Goals

Robert Cowan, MD;David W. Dodick, MD
October 30th 2020
Treatment Goals for Acute Migraine

Treatment Goals for Acute Migraine

Robert Cowan, MD;David W. Dodick, MD
October 30th 2020
Treating Acute Migraine in the Community Setting

Treating Acute Migraine in the Community Setting

Robert Cowan, MD;David W. Dodick, MD
October 30th 2020
Acute Migraine Treatment: What’s Next?

Acute Migraine Treatment: What’s Next?

Robert Cowan, MD;David W. Dodick, MD
October 30th 2020
Real-World Experience With Gepants for Acute Migraine

Real-World Experience With Gepants for Acute Migraine

Robert Cowan, MD;David W. Dodick, MD
October 30th 2020
Gepants for Acute Migraine: Patient Management

Gepants for Acute Migraine: Patient Management

Robert Cowan, MD;David W. Dodick, MD
October 30th 2020
Gepants for Acute Migraine: Safety & Efficacy Data

Gepants for Acute Migraine: Safety & Efficacy Data

Robert Cowan, MD;David W. Dodick, MD
October 30th 2020
Advances in the Treatment of Acute Migraine

Advances in the Treatment of Acute Migraine

Robert Cowan, MD;David W. Dodick, MD
October 30th 2020
Burden of Migraine

Burden of Migraine

Robert Cowan, MD;David W. Dodick, MD
October 30th 2020
©ESPProfessional/Shutterstock

Welcome Inside the Box, Circa 1990!

Robert Cowan, MD
May 9th 2018

With approximately 500 board-certified headache specialists and just over 60 million Americans with headache, the average wait time to see one of us is 3 to 4 months. Technology may hold the key to issues such as this.

Latest Updated Articles

Jannis Müller, MD, MSc (Credit: LinkedIn)
Published: May 14th 2025 | Updated: May 16th 2025
Observed Differences in PIRA Definition Call for More Standardized Agreement on Term
Giulia Fadda, MD (Credit: Ottawa Hospital Research Institute)
Published: May 12th 2025 | Updated: May 13th 2025
Serum Neurofilament Light Chain Limited in Predicting MOGAD Attacks but Correlates With Attack Severity
FDA Approves Diazoxide Choline Extended-Release Tablets for Hyperphagia in Prader-Willi Syndrome
Published: March 27th 2025 | Updated: March 28th 2025
FDA Approves Diazoxide Choline Extended-Release Tablets for Hyperphagia in Prader-Willi Syndrome
BTK Inhibitor Tolebrutinib Shows Greater Effectiveness in Multiple Sclerosis with Higher Paramagnetic Rim Lesion Counts
Published: March 4th 2025 | Updated: March 19th 2025
BTK Inhibitor Tolebrutinib Shows Greater Effectiveness in Multiple Sclerosis with Higher Paramagnetic Rim Lesion Counts
FDA Approves Vertex Pharmaceuticals' Suzetrigine for Acute Pain Management
Published: January 30th 2025 | Updated: February 21st 2025
FDA Approves Vertex Pharmaceuticals' Suzetrigine for Acute Pain Management
Cerebrospinal Fluid Lipids Shows Promise as Biomarkers for Differentiating NMOSD and MS
Published: February 15th 2025 | Updated: February 18th 2025
Cerebrospinal Fluid Lipids Shows Promise as Biomarkers for Differentiating NMOSD and MS
© 2025 MJH Life Sciences

All rights reserved.